doi.org/10.1016/s0140-6736(17)33095-7

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

..., Kati Vandermeulen
18
The Lancet98.40
Volume: 391, Issue: 10123, Pages: 839 - 849
Published: Mar 1, 2018
Paper Fields
Paper Details
Title
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
DOI
doi.org/10.1016/s0140-6736(17)33095-7
Published Date
Mar 1, 2018
Journal
The Lancet
Volume
391
Issue
10123
Pages
839 - 849
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.